Drug carriers for oral delivery of peptides and proteins: accomplishments and future perspectives

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Wawrezinieck A, Péan J-M, Wüthrich P, Benoit J-P. Biodisponibilitéet vecteurs particulaires pour la voieorale. Med. Sci.24(6–7),659–664 (2008).
  Google Scholar
• 2  Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov. Today11(19–20),905–910 (2006).
  Medline CASGoogle Scholar
• 3  Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. Nanoencapsulation II. Biomedical applicaions and current status of peptide and protein nanoparticulate delivery systems. Nanomedicine2(2),53–65 (2006).▪ Covers some of the historical and recent advances of nanotechnology and concludes that polymeric nanoparticles show great promise as a tool for the development of peptide drug-delivery systems.
  Medline CASGoogle Scholar
• 4  Shaji J, Patole V. Protein and peptide drug delivery: oral approaches. Indian J. Pharm. Sci.70(3),269–277 (2008).
  MedlineGoogle Scholar
• 5  Almeida AJ, Souto E. Solid lipid nanoparticles as a drug delivery system for peptides and proteins. Adv. Drug Deliv. Rev.59(6),478–490 (2007).▪ Review of solid lipid particulate systems as platforms to incorporate or adsorb peptides and proteins for administration by alternative routes such as oral, nasal and pulmonary.
  Medline CASGoogle Scholar
• 6  Kamei N, Morishita M, Chiba H, Kavimandan NJ, Peppas NA, Takayama K. Complexation hydrogels for intestinal delivery of interferon beta and calcitonin. J. Control. Release134(2),98–102 (2009).
  Medline CASGoogle Scholar
• 7  Martins S, Sarmento B, Ferreira DC, Souto EB. Lipid-based colloidal carriers for peptide and protein delivery – liposomes versus lipid nanoparticles. Int. J. Nanomedicine2(4),595–607 (2007).
  Medline CASGoogle Scholar
• 8  Hamman JH, Demana PH, Olivier EI. Targeting receptors, transporters and site of absorption to improve oral drug delivery. Drug Target Insights2,71–81 (2007).
  Medline CASGoogle Scholar
• 9  Fogueri LR, Singh S. Smart polymers for controlled delivery of proteins and peptides: a review of patents. Recent Pat. Drug Deliv. Formul.3(1),40–48 (2009).▪▪ Interesting review of new technologies to improve proteins absorption by different routes of administration. Focus on patented technologies and common limitations found for protein delivery.
  Medline CASGoogle Scholar
• 10  Slomkowski S, Gosecki M. Progress in nanoparticulate systems for peptide, proteins and nucleic acid drug delivery. Curr. Pharm. Biotechnol.12(11),1823–1839 (2011).
  Medline CASGoogle Scholar
• 11  Xia CQ, Wang J, Shen W-C. Hypoglycemic effect of insulin-transferrin conjugate in streptozotocin-induced diabetic rats. J. Pharmacol. Exp. Ther.295(2),594–600 (2000).
  Medline CASGoogle Scholar
• 12  Mishra B, Patel BB, Tiwari S. Colloidal nanocarriers: a review on formulation technology, types and applications toward targeted drug delivery. Nanomedicine6(1),9–24 (2010).
  Medline CASGoogle Scholar
• 13  Mahato R, Narang A, Thoma L, Miller D. Emerging trends in oral delivery of peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst.20(2–3),153–214 (2003).
  Medline CASGoogle Scholar
• 14  Muller G. Oral delivery of protein drugs: driver for personalized medicine. Curr. Issues Mol. Biol.13(1),13–24 (2011).
  MedlineGoogle Scholar
• 15  Laulicht B, Gidmark N, Tripathi A, Mathiowitz E. Localization of magnetic pills. Proc. Natl Acad. Sci. USA108(6),2252–2257 (2011).
  Medline CASGoogle Scholar
• 16  Werle M, Makhlof A, Takeuchi H. Carbopol–lectin conjugate coated liposomes for oral peptide delivery. Chem. Pharm. Bull58(3),432–434 (2010).
  Medline CASGoogle Scholar
• 17  Bernkop-Schnürch A. Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int. J. Pharm.194(1),1–13 (2000).
  Medline CASGoogle Scholar
• 18  Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev.64(6),557–570 (2012).▪▪ Summary of the main problems and challenges for oral drug delivery and how nanotechnology can be an alternative to poor drug absorption or instability. The authors backup a complete ‘state of art’ about mucoadhesion and oral barriers.
  Medline CASGoogle Scholar
• 19  Filipe V, Hawe A, Jiskoot W. Critical evaluation of nanoparticle tracking analysis (NTA) by nanosight for the measurement of nanoparticles and protein aggregates. Pharm. Res.27(5),796–810 (2010).
  Medline CASGoogle Scholar
• 20  Guggi D, Kast C, Bernkop-Schnürch A. In vivo evaluation of an oral salmon calcitonin-delivery system based on a thiolated chitosan carrier matrix. Pharm. Res.20(12),1989–1994 (2003).
  Medline CASGoogle Scholar
• 21  Park K, Kwon IC, Park K. Oral protein delivery: current status and future prospect. React. Funct. Polym.71(3),280–287 (2011).
  CASGoogle Scholar
• 22  Ankola DD, Ravi KMNV, Chiellini F, Solaro R. Multiblock copolymers of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups: synthesis, characterization, and nanoparticle preparation. Macromolecules.42(19),7388–7395 (2009).
  CASGoogle Scholar
• 23  Balamuralidhara V, Pramodkumar TM, Srujana N et al. pH sensitive drug delivery systems: a review. Am. J. Drug Discov. Dev.1,24–48 (2011).
  Google Scholar
• 24  desRieux A, Fievez V, Garinot M, Schneider Y-J, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release116(1),1–27 (2006).▪▪ Important review of several carriers and their mechanistic absorption both in vitro and in vivo. Comprehensive description of the different factors that contribute to oral absorption of micro- and nano-particles.
  Medline CASGoogle Scholar
• 25  Niu M, Lu Y, Hovgaard L, Wu W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int. J. Nanomedicine6,1155–1166 (2011).
  Medline CASGoogle Scholar
• 26  Behrens I, Pena AI, Alonso MJ, Kissel T. Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res.19(8),1185–1193 (2002).
  Medline CASGoogle Scholar
• 27  Brayden D, Mrsny R. Oral peptide delivery: prioritizing the leading technologies. Ther. Deliv.2(12),1567–1573 (2011).
  CASGoogle Scholar
• 28  Rajeswari TS. Non invasiveinsulins: advanced insulin therapy over this decade. J. App. Pharm. Sci.1(8),12–20 (2011).
  Google Scholar
• 29  Amory JK, Leonard ST, Page ST, O’Toole E, McKenna MJ. Oral administration of the GnRH antagonist acyline, in a GIPET-enhanced tablet form, acutely suppresses serum testosterone in normal men: single-dose pharmacokinetics and pharmacodynamics. Cancer Chemother. Pharmacol.64(3),641–645 (2009).
  Medline CASGoogle Scholar
• 30  Soltero R, Soltero R. Oral protein and peptide drug delivery. In: Drug Delivery: Principles and Applications. Wang B, Siahaan TJ, Soltero R (Eds). John Wiley & Sons, Inc., Hoboken, NJ, USA, 189–200 (2005).
  Google Scholar
• 31  Kamei N, Morishita M, Eda Y, Ida N, Nishio R, Takayama K. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J. Control. Release132(1),21–25 (2008).
  Medline CASGoogle Scholar
• 32  Makhlof A, Werle M, Tozuka Y, Takeuchi H. A mucoadhesive nanoparticulate system for the simultaneous delivery of macromolecules and permeation enhancers to the intestinal mucosa. J. Control. Release149(1),81–88 (2011).
  Medline CASGoogle Scholar
• 33  Bajpai AK, Shukla SK, Bhanu S, Kankane S. Responsive polymers in controlled drug delivery. Prog. Polym. Sci.33(11),1088–1118 (2008).
  CASGoogle Scholar
• 34  Varshosaz J. Insulin delivery systems for controlling diabetes. Recent Pat. Endocr. Metab. Immune Drug Discov.1,25–40 (2007).
  CASGoogle Scholar
• 35  Jafari B, Rafie F, Davaran S. Preparation and characterization of a novel smart polymeric hydrogel for drug delivery of insulin. Bio. Impacts.1(2),135–143 (2011).
  CASGoogle Scholar
• 36  Mundargi RC, Rangaswamy V, Aminabhavi TM. pH-sensitive oral insulin delivery systems using eudragit microspheres. Drug Dev. Ind. Pharm.37(8),977–985 (2011).
  Medline CASGoogle Scholar
• 37  Shofner JP, Phillips MA, Peppas NA. Cellular evaluation of synthesized insulin/transferrin bioconjugates for oral insulin delivery using intelligent complexation hydrogels. Macromol. Biosci.10(3),299–306 (2010).
  Medline CASGoogle Scholar
• 38  Lin C-C, Anseth KS. Glucagon-like peptide-1 functionalized PEG hydrogels promote survival and function of encapsulated pancreatic beta-cells. Biomacromolecules10(9),2460–2467 (2009).
  Medline CASGoogle Scholar
• 39  Carr DA, Peppas NA. Assessment of poly(methacrylic acid-co-N-vinyl pyrrolidone) as a carrier for the oral delivery of therapeutic proteins using Caco-2 and HT29-MTX cell lines. J. Biomed. Mater. Res. A.92A(2),504–512 (2010).
  CASGoogle Scholar
• 40  Wood KM, Stone GM, Peppas NA. The effect of complexation hydrogels on insulin transport in intestinal epithelial cell models. Acta. Biomater.6,48–56 (2010).
  Medline CASGoogle Scholar
• 41  Kavimandan NJ, Peppas NA. Confocal microscopic analysis of transport mechanisms of insulin across the cell monolayer. Int. J. Pharm.354,143–148 (2008).
  Medline CASGoogle Scholar
• 42  Wood KM, Stone GM, Peppas NA. Wheat germ agglutinin functionalized complexation hydrogels for oral insulin delivery. Biomacromolecules9(4),1293–1298 (2008).
  Medline CASGoogle Scholar
• 43  Sajeesh S, Bouchemal K, Marsaud V, Vauthier C, Sharma CP. Cyclodextrincomplexed insulin encapsulated hydrogel microparticles: an oral delivery system for insulin. J. Control. Release147(3),377–384 (2010).
  Medline CASGoogle Scholar
• 44  Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv. Drug Deliv. Rev.53(1),321–339 (2012).
  Google Scholar
• 45  Laroui H, Sitaraman SV, Merlin D. Gastrointestinal delivery of anti-inflammatory nanoparticles. Methods Enzymol.509,101–125 (2012).
  Medline CASGoogle Scholar
• 46  He C, Yin L, Tang C, Yin C. Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs. Biomaterials33(33),8569–8578 (2012).
  Medline CASGoogle Scholar
• 47  Wang AZ, Gu F, Zhang L et al. Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin. Biol.Ther.8(8),1063–1070 (2008).
  Medline CASGoogle Scholar
• 48  Damgé C, Vranckx H, Balschmidt P, Couvreur P. Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci.86(12),1403–1409 (1997).
  Medline CASGoogle Scholar
• 49  Damgé C, Michel C, Aprahamian M, Couvreur P, Devissaguet JP. Nanocapsules as carriers for oral peptide delivery. J. Control. Release13(2–3),233–239 (1990).
  CASGoogle Scholar
• 50  Russell-Jones GJ, Arthur L, Walker H. Vitamin B12-mediated transport of nanoparticles across CACO-2 cells. Inter. J. Pharm.179(2),247–255 (1999).
  Medline CASGoogle Scholar
• 51  LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat. Biotech.21(10),1184–1191 (2003).
  Medline CASGoogle Scholar
• 52  Mansour H, Sohn M, Al-Ghananeem A, Deluca P. Materials for pharmaceutical dosage forms: molecular pharmaceutics and controlled release drug delivery aspects. Int. J. Mol. Sci.11(9),3298–3322 (2010).
  Medline CASGoogle Scholar
• 53  Kayser O, Lemke A, Hernández-Trejo N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr. Pharm. Biotechnol.6(1),3–5 (2005).
  Medline CASGoogle Scholar
• 54  Deacon MP, Davis SS, White RJ et al. Are chitosan–mucin interactions specific to different regions of the stomach? Velocity ultracentrifugation offers a clue. Carbohydr. Polym.38,235–238 (1999).
  CASGoogle Scholar
• 55  Sreenivas S, Pai K. Thiolated chitosans: novel polymers for mucoadhesive drug delivery – a review. Trop. J. Pharm. Res.7(3),1077–1088 (2008).
  Google Scholar
• 56  Sonaje K, Chen Y-J, Chen H-L et al. Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials31(12),3384–3394 (2010).
  Medline CASGoogle Scholar
• 57  Yin L, Ding J, He C, Cui L, Tang C, Yin C. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials30(29),5691–5700 (2009).
  Medline CASGoogle Scholar
• 58  Luessen H, Verhoef J, Borchard G, Lehr C, de Boer A, Junginger H. Mucoadhesive polymers in peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm. Res.12(9),1293–1298 (1995).
  Medline CASGoogle Scholar
• 59  Sarmento B, Ribeiro A, Veiga F, Sampaio P, Neufeld R, Ferreira D. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharm. Res.24(12),2198–2206 (2007).
  Medline CASGoogle Scholar
• 60  Zhang Y, Wei W, Lv P, Wang L, Ma G. Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin. Eur. J. Pharm. Biopharm.7(1),11–19 (2011).
  CASGoogle Scholar
• 61  Cheng J, Teply B, Jeong S et al. Magnetically responsive polymeric microparticles for oral delivery of protein drugs. Pharm. Res.23(3),557–564 (2006).
  Medline CASGoogle Scholar
• 62  Si L, Zhao Y, Huang J, Li S, Zhai X, Li G. Calcium pectinate gel bead intended for oral protein delivery: preparation improvement and formulation development. Chem. Pharm. Bull.57(7),663–667 (2009).
  Medline CASGoogle Scholar
• 63  Damgé C, Michel C, Aprahamian M, Couvreur P. New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes37(2),246–251 (1988).
  Medline CASGoogle Scholar
• 64  Damgé C, Aprahamian M, Humbert W, Pinget M. Ileal uptake of polyalkylcyanoacrylate nanocapsules in the rat. J. Pharm. Pharmacol.52(9),1049–1056 (2000).
  Medline CASGoogle Scholar
• 65  Damgé C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control. Release117(2),163–170 (2007).
  Medline CASGoogle Scholar
• 66  Peppas N, Thomas J, McGinty J. Molecular aspects of mucoadhesive carrier development for drug delivery and improved absorption. J. Biomater. Sci. Polym. Ed.20(1),1–20 (2009).
  Medline CASGoogle Scholar
• 67  Kajal H, Misra A. Preparation of tetanus toxoid and ovalbumin loaded gliadin nanoparticles for oral immunization. J. Biomed. Nanotechnol.7(1),211–212 (2011).
  Medline CASGoogle Scholar
• 68  Sarti F, Perera G, Hintzen F et al.In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A. Biomaterials32(16),4052–4057 (2011).
  Medline CASGoogle Scholar
• 69  Oostingh G, Casals E, Italiani P et al. Problems and challenges in the development and validation of human cell-based assays to determine nanoparticle-induced immunomodulatory effects. Part Fibre Toxicol.8(1),8 (2011).
  Medline CASGoogle Scholar
• 70  Garinot M, Fiévez V, Pourcelle V et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J. Control. Release120(3),195–204 (2007).
  Medline CASGoogle Scholar
• 71  Shahiwala A, Vyas T, Amiji M. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat. Drug Deliv. Formul.1(1),1–9 (2007).
  Medline CASGoogle Scholar
• 72  Fievez V, Plapied L, des Rieux A et al. Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination. Eur. J. Pharm. Biopharm.73(1),16–24 (2009).▪ Possible use of peptide and nonpeptide ligands for targeting M cells and how their own stability in the GI tract may affect the efficacy of nanoparticles uptake.
  Medline CASGoogle Scholar
• 73  Shakweh M, Ponchel G, Fattal E. Particle uptake by Peyer’s patches: a pathway for drug and vaccine delivery. Expert Opin. Drug Deliv.1(1),141–163 (2004).
  Medline CASGoogle Scholar
• 74  van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur. J. Pharm. Sci.14(3),201–207 (2001).
  Medline CASGoogle Scholar
• 75  Tobio M, Sánchez A, Vila A et al. The role of PEG on the stability in digestive fluids and in vivo fate of PEG-PLA nanoparticles following oral administration. Colloids Surf. B Biointerfaces18(3–4),315–323 (2000).
  Medline CASGoogle Scholar
• 76  Manosroi J, Apriyani MG, Foe K, Manosroi A. Enhancement of the release of azelaic acid through the synthetic membranes by inclusion complex formation with hydroxypropyl-beta-cyclodextrin. Int. J. Pharm.293(1–2),235–240 (2005).
  Medline CASGoogle Scholar
• 77  Karande P, Mitragotri S. Enhancement of transdermal drug delivery via synergistic action of chemicals. Biochim. Biophys. Acta.1788(11),2362–2373 (2009).
  Medline CASGoogle Scholar
• 78  Lopez RFV, Seto JE, Blankschtein D, Langer R. Enhancing the transdermal delivery of rigid nanoparticles using the simultaneous application of ultrasound and sodium lauryl sulfate. Biomaterials32(3),933–941 (2011).
  Medline CASGoogle Scholar
• 79  Lambert D, O’Neill C, Padfield P. Depletion of Caco-2 cell cholesterol disrupts barrier function by altering the detergent solubility and distribution of specific tight-junction proteins. Biochem J.15(387-Pt2),553–560 (2005).
  Google Scholar
• 80  Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS Pharm. Sci. Tech.6,E329–E357 (2005).
  MedlineGoogle Scholar
• 81  Yuan Q, Lee E, Yeudall WA, Yang H. Dendrimer-triglycine-EGF nanoparticles for tumor imaging and targeted nucleic acid and drug delivery. Oral Oncol.46(9),698–704 (2010).
  Medline CASGoogle Scholar
• 82  Bhavsar MD, Tiwari SB, Amiji MM. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J. Control. Release110(2),422–430 (2006).
  Medline CASGoogle Scholar
• 83  Nishino Y, Kubota A, Kanazawa T, Takashima Y, Ozeki T, Okada H. Improved intestinal absorption of a poorly water-soluble oral drug using mannitolmicroparticles containing a nanosolid drug dispersion. J. Pharm. Sci.101(11),4191–4200 (2012).
  Medline CASGoogle Scholar
• 84  Gundogdu E, Gonzalez AI, Karasulu E. Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies. Int. J. Nanomedicine6,1631–1640 (2011).
  Medline CASGoogle Scholar
• 85  Cilek A, Celebi N, Tirnaksiz F, Tay A. A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: Investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats. Int. J. Pharm.298(1),176–185 (2005).
  Medline CASGoogle Scholar
• 86  Lv L, Tong C, Lv Q et al. Enhanced absorption of hydroxysafflor yellow A using a self-double-emulsifying drug delivery system: in vitro and in vivo studies. Int. J. Nanomedicine7,4099–4107 (2012).
  Medline CASGoogle Scholar
• 87  Qi X, Wang L, Zhu J, Hu Z, Zhang J. Self-double-emulsifying drug delivery system (SDEDDS): a new way for oral delivery of drugs with high solubility and low permeability. Int. J. Pharm.409(1–2),245–251 (2011).
  Medline CASGoogle Scholar
• 88  Lu Y, Park K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm. (2012) (In Press).
  Google Scholar
• 89  Korting HC, Schäfer-Korting M. Carriers in the topical treatment of skin disease. In: Drug delivery. Schäfer-Korting M (Ed.). Springer Berlin Heidelberg, Germany 435–468 (2010).▪▪ Important text describing current status of different carriers for skin delivery and their relevance for clinical applications.
  Google Scholar
• 90  Wang S, Tan M, Zhong Z, Chen M, Wang Y. Nanotechnologies for curcumin: an ancient puzzler meets modern solutions. J. Nanomaterials Article ID 723178 (2011).
  MedlineGoogle Scholar
• 91  Fricker G, Kromp T, Wendel A et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharm. Res.27(8),1469–1486 (2010).
  Medline CASGoogle Scholar
• 92  Torchilin V. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug. Discov.4(2),145–160 (2005).▪ Important overview of liposomes including their absorption, different technologies explored to improve their characteristics and their relevance for clinical setting.
  Medline CASGoogle Scholar
• 93  Schaffazick SR, Pohlmann AR, de Cordova CAS, Creczynski-Pasa TB, Guterres SS. Protective properties of melatonin-loaded nanoparticles against lipid peroxidation. Int. J. Pharm.289(1–2),209–213 (2005).
  Medline CASGoogle Scholar
• 94  Arayne M, Sultana N, Qureshi F. Review: nanoparticles in delivery of cardiovascular drugs. Pak. J. Pharm. Sci.20(4),340–348 (2007).
  Medline CASGoogle Scholar
• 95  Kalra S, Kalra B, Agrawal N. Oral insulin. Diabetol. Metab. Syndr.2(66), (2010).
  Google Scholar
• 96  Imanaka H, Koide H, Shimizu K et al. Chemoprevention of tumor metastasis by liposomal and beta-sitosterol intake. Biol. Pharm. Bull.31(3),400–404 (2008).
  Medline CASGoogle Scholar
• 97  Geho W, Geho H, Lau J, Gana T. Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J. Diabetes Sci. Technol.3(6),1451–1459 (2009).
  MedlineGoogle Scholar
• 98  Han H-K, Shin H-J, Ha DH. Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system. Eur. J. Pharm. Sci.46(5),500–507 (2012).
  Medline CASGoogle Scholar
• 99  Chung H, Kim J, Um JY, Kwon IC, Jeong SY. Self-assembled “nanocubicle” as a carrier for peroral insulin delivery. Diabetologia45(3),448–451 (2002).
  Medline CASGoogle Scholar
• 100  Lai J, Lu Y, Yin Z, Hu F, Wu W. Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glycerylmonooleate/poloxamer 407 cubic nanoparticles. Int. J. Nanomedicine5,13–23 (2010).
  Medline CASGoogle Scholar
• 101  Yang M, Lai SK, Wang Y-Y et al. Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew. Chem. Int. Ed. Engl.50(11),2597–2600 (2011).
  Medline CASGoogle Scholar
• 102  Yang R, Gao R, Li F, He H, Tang X. The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process. Drug Dev. Ind. Pharm.37(2),139–148 (2010).
  MedlineGoogle Scholar
• 103  Elgart A, Cherniakov I, Aldouby Y, Domb AJ, Hoffman A. Lipospheres and pro-nanolipospheres for delivery of poorly water soluble compounds. Chem. Phys. Lipids.165(4),438–453 (2012).
  Medline CASGoogle Scholar
• 104  Kapitza C, Zijlstra E, Heinemann L, Castelli MC, Riley G, Heise T. Oral insulin: a comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care33(6),1288–1290 (2010).
  Medline CASGoogle Scholar
• 105  Lee S, Lee J, Lee D, Kim S, Lee Y, Byun Y. A new drug carrier, N alpha-deoxycholyl-L-lysyl-methylester, for enhancing insulin absorption in the intestine. Diabetologia48(3),405–411 (2005).
  Medline CASGoogle Scholar
• 106  Wei W, Ma G-H, Wang L-Y, Wu J, Su Z-G. Hollow quaternized chitosan microspheres increase the therapeutic effect of orally administered insulin. Acta. Biomater.6(1),205–209 (2010).
  Medline CASGoogle Scholar
• 107  Morçöl T, Nagappan P, Nerenbaum L, Mitchell A, Bell SJD. Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. Int. J. Pharm.277(1–2),91–97 (2004).
  Medline CASGoogle Scholar
• 108  He Q, Mitchell A, Johnson S, Wagner-Bartak C, Morcol T, Bell SJ. Calcium phosphate nanoparticle adjuvant. Clin. Diagn. Lab. Immunol.7(6),899–903 (2000).
  Medline CASGoogle Scholar
• 109  Paul W, Sharma CP. Fatty acid conjugated calcium phosphate nanoparticles for protein delivery. Int. J. Appl. Ceram. Tec.7(2),129–138 (2010).
  CASGoogle Scholar
• 110  Chen L, Liu L, Li C, Tan Y, Zhang, G. A new growth factor controlled drug release system to promote healing of bone fractures: nanospheres of recombinant human bone morphogenetic-2 and polylactic acid. J. Nanosci. Nanotechnol.11(4),3107–3114 (2011).
  Medline CASGoogle Scholar
• 111  Norman P. Diabetes pipeline: intense activity to meet unmet need report–overview. Cambridge Healthtech Institute, Cambridge, MA, USA (2010).
  Google Scholar
• 201  Zion TC, Tsang HH, Ying JY. Glucose-sensitive nanoparticles for controlled insulin delivery. MEBCS (2003). http://hdl.handle.net/1721.1/3783
  Google Scholar
• 202  Merrion Pharmaceuticals. www.merrionpharma.com/content/potfolio/pipeline.asp
  Google Scholar
• 203  Pinto-Reis AC. Encapsulação de fármacos peptídicos pelo método de emulsificação/gelificação interna. Universidade de Coimbra, 2009. PhD Thesis. http://hdl.handle.net/10316/213
  Google Scholar
• 204  Emisphere, ‘Oral GLP-1 for Type 2 diabetes’. www.emisphere.com/oral_GLP-1.html
  Google Scholar
• 205  Emisphere, ‘Oral recombinant human growth hormone’. www.emisphere.com/oral_reconbinant_hgh.html
  Google Scholar
• 206  Emisphere, ‘Salmon Calcitonin for Osteoarthritis and Osteoporosis’. www.emisphere.com/salmon_calcitonin.html
  Google Scholar